SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Summit Therapeutics Inc (SMMT) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are bearish, options data shows mixed sentiment, and the financial performance remains weak. While there are positive catalysts in the form of ongoing clinical trials and FDA acceptance of the Biologics License Application, the near-term uncertainty and lack of strong trading signals suggest holding off on investment for now.
The MACD is negatively expanding, RSI is neutral at 37.49, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 15.7, with key support at 14.864 and resistance at 16.537. The technical indicators suggest a bearish trend.
FDA acceptance of the Biologics License Application for the HARMONi trial with a target approval date in November
Participation in multiple investor conferences in March
Ongoing Phase III trials for Ivonescimab (SMT
with over 4,000 patients treated globally.
Absence of updated HARMONi-2 and HARMONi-6 overall survival analyses, creating near-term uncertainty.
Analysts have lowered price targets due to the lack of updates.
Stock trend analysis indicates an 80% chance of short-term price declines (-6.54% next day, -9.66% next week).
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$219.17M (up 258.11% YoY), and an EPS of -0.29 (up 262.50% YoY). While there is improvement in EPS and net income, the company remains unprofitable with no revenue growth.
Analysts maintain a generally positive outlook with Buy ratings, but price targets have been adjusted downward. Citi has a $40 price target citing potential FDA engagement, while H.C. Wainwright lowered its target to $30 due to near-term uncertainty. Barclays upgraded the stock to Equal Weight with an $18 price target, citing meaningful lung cancer updates in 2026.
